Nevertheless, advances offer hope: SCLC originates from airway basal cells with “trunk-branch” heterogeneity (basal-like trunk, NE/tuft/Atoh1+ targetable branches) (54, 183), explaining short-term efficacy followed by recurrence and guiding dynamic monitoring/trunk targeting. Here, ATOH1 is linked to small cell lung carcinoma.